close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aptevo Therapeutics Inc. - Common Stock (NQ:APVO)

0.7450 -0.3350 (-31.02%)
Delayed Quote Updated: 3:16 PM EST, Nov 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aptevo Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
Aptevo Therapeutics Announces Exercise of Existing Warrants for $3.0 Million Gross Proceeds
From Aptevo Therapeutics
Via ACCESS Newswire
News headline image
Aptevo Presents Preclinical Data at SITC 2026 Showing Potential to Overcome Immune Suppression in Solid Tumors
In lab studies, APVO451 and APVO452 helped immune cells kill cancer cells despite conditions that suppress immune activity - offering potential for difficult-to-treat solid tumors Preclinical work also... 
From Aptevo Therapeutics
Via ACCESS Newswire
News headline image
Aptevo Achieves Key Clinical Development Objective, Significantly Reducing Infusion-Related Reactions with Mipletamig in Frontline AML
Refined priming-dose regimen addresses important treatment-tolerability objective identified through FDA discussions, further strengthening mipletamig's readiness for Phase 2 development Substantial... 
From Aptevo Therapeutics
Via ACCESS Newswire
News headline image
Aptevo Reports Mipletamig Combination Therapy Enabled 21% of Frontline AML Patients to Advance to Potentially Curative Stem Cell Transplant
Ten patients initially deemed unfit for intensive chemotherapy proceeded to stem cell transplant Transplant rate compares favorably with historical standard-of-care experience, adding to growing... 
From Aptevo Therapeutics
Via ACCESS Newswire
News headline image
Aptevo to Showcase Multispecific Platform at SITC 2026 Annual Meeting
Next generation multispecific technology designed to coordinate innate and adaptive immune activity within the tumor microenvironment 
From Aptevo Therapeutics
Via ACCESS Newswire
News headline image
Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development
Company Making Critical Progress in Scalable Manufacturing and Preparing the Lead Trispecific Candidate for Future Human Testing Trispecifics Combine Three Complementary Cancer-Fighting Functions in... 
From Aptevo Therapeutics
Via ACCESS Newswire
The trading volume of these stocks is deviating from the norm in today's session. ↗
Via Chartmill
News headline image
Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML
From Aptevo Therapeutics
Via ACCESS Newswire
News headline image
Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results
From Aptevo Therapeutics
Via ACCESS Newswire
News headline image
Aptevo Therapeutics Announces Closing of Existing Warrants Exercise and PIPE for $4.5 Million Gross Proceeds
From Aptevo Therapeutics
Via ACCESS Newswire
News headline image
Aptevo Therapeutics Announces Exercise of Existing Warrants and PIPE for $4.5 Million Gross Proceeds
From Aptevo Therapeutics
Via ACCESS Newswire
News headline image
Aptevo Strengthens Solid Tumor Strategy with Patent Filing for Nectin-4 x PD-L1 Dual Targeting Backbone
From Aptevo Therapeutics
Via ACCESS Newswire
News headline image
Aptevo Secures $1.5 Million Non-Dilutive Research Grant From the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors
From Aptevo Therapeutics
Via ACCESS Newswire
News headline image
As Big Pharma Bets On Radiopharmaceuticals, Aptevo And Niowave Join Forces To Advance Novel Targeted Cancer Therapeutics In The $17B+ Oncology Category
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
Aptevo Therapeutics Appoints Mary J. Janatpour, Ph.D., as Senior Vice President & Chief Scientific Officer
Via ACCESS Newswire
News headline image
Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closing
Via ACCESS Newswire
News headline image
Aptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection
Via ACCESS Newswire
News headline image
Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection
Via ACCESS Newswire
News headline image
Aptevo's Mipletamig Shows 86% Clinical Benefit Rate In Frontline AML As Emerging Data Demonstrate Additive Benefit To Standard Of Care Treatment
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
Aptevo Provides State of the Business Report and 2025 Financial Results
Via ACCESS Newswire
News headline image
Aptevo to Participate in March 2026 Conferences
Via ACCESS Newswire
Gapping stocks in Tuesday's session ↗
Via Chartmill
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill
News headline image
Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50%
Via ACCESS Newswire
News headline image
Aptevo Announces Executive Leadership Transitions to Support Next Phase of Growth
Via ACCESS Newswire
Friday's pre-market session: top gainers and losers ↗
Via Chartmill
News headline image
Aptevo Therapeutics Secures $60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic Optionality
Via ACCESS Newswire
News headline image
These stocks are moving in today's session ↗
Looking for insights into the US markets one hour before the close of the markets on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
News headline image
Top movers in Friday's session ↗
Keep an eye on the top gainers and losers in Friday's session, as they reflect the most notable price movements. 
Via Chartmill
News headline image
Aptevo Therapeutics Stock Slumps To All-Time Low On Reverse Split Approval ↗
The move will cut Aptevo’s issued and outstanding shares from about 18 million to roughly a million. 
Via Stocktwits
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.